Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Name: Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
Author: Kazandjian, Dickran

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. — المؤلف: Kazandjian, Dickran — JAMA oncology 20191022

المؤلف: Kazandjian, Dickran
النشر: JAMA oncology 20191022
الوصف: 1781-1783 p.
الموضوعات: Adult؛ Aged؛ Aged, 80 and over؛ Antineoplastic Combined Chemotherapy Protocols؛ Dexamethasone؛ Drug Resistance, Neoplasm؛ Female؛ Follow-Up Studies